Screening Interested participants will sign the appropriate informed consent form (ICF) prior to completion of any study procedures.~The investigator will review symptoms, risk factors and other non-invasive inclusion and exclusion criteria prior to any invasive procedures. If the participant is eligible after this review, then the site will perform the invasive procedures to confirm eligibility.~Treatment and Assessment Period~This is the general sequence of events during the 29-day treatment and assessment period:~Complete baseline procedures and sample collection~Participants are randomized to an intervention group~Participants receive study intervention (Q12H X 5 days), and~Complete all safety monitoring.~Blood samples collection
The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) for the Treatment of Coronavirus Disease 2019 (COVID-19) in participants with moderate to severe COVID-19.